Urothelial carcinoma in situ - Revision history

Michael: /* Images */

2016-11-23T04:56:02Z

Images

← Older revision		Revision as of 04:56, 23 November 2016
Line 73:		Line 73:
	===Images===		===Images===
	<gallery>		<gallery>
	Image: Urothelial carcinoma in situ -- intermed mag.jpg \| UCIS - intermed. mag.		Image: Urothelial carcinoma in situ -- intermed mag.jpg \| UCIS - intermed. mag. (WC)
	Image: Urothelial carcinoma in situ -- high mag.jpg \| UCIS - high mag.		Image: Urothelial carcinoma in situ -- high mag.jpg \| UCIS - high mag. (WC)
	Image: Urothelial carcinoma in situ - alt -- high mag.jpg \| UCIS - high mag.		Image: Urothelial carcinoma in situ - alt -- high mag.jpg \| UCIS - high mag. (WC)
	Image: Urothelial carcinoma in situ -- very high mag.jpg \| UCIS - very high mag.		Image: Urothelial carcinoma in situ -- very high mag.jpg \| UCIS - very high mag. (WC)
	</gallery>		</gallery>
	www:		<gallery>
			Image: Urothelial CIS -- low mag.jpg \| UCIS - low mag. (WC)
			Image: Urothelial CIS -- intermed mag.jpg \| UCIS - intermed. mag. (WC)
			Image: Urothelial CIS -- high mag.jpg \| UCIS - high mag. (WC)

			Image: Urothelial CIS - CK20 -- intermed mag.jpg \| UCIS - CK20 - intermed. mag. (WC)
			Image: Urothelial CIS - p63 -- intermed mag.jpg \| UCIS - p63 - intermed. mag. (WC)
			Image: Urothelial CIS - Ki67 -- high mag.jpg \| UCIS - Ki-67 - high mag. (WC)
			</gallery>
			====www====
	*[http://www.webpathology.com/image.asp?n=7&Case=57 Urothelial CIS (webpathology.com)].		*[http://www.webpathology.com/image.asp?n=7&Case=57 Urothelial CIS (webpathology.com)].
	*[http://www.webpathology.com/image.asp?n=10&Case=57 Urothelial CIS with shedding (webpathology.com)].		*[http://www.webpathology.com/image.asp?n=10&Case=57 Urothelial CIS with shedding (webpathology.com)].

Michael: /* IHC */

2015-06-17T21:20:07Z

IHC

← Older revision		Revision as of 21:20, 17 June 2015
Line 99:		Line 99:
	*CD44 -ve.<ref name=pmid24225842>{{Cite journal \| last1 = Aron \| first1 = M. \| last2 = Luthringer \| first2 = DJ. \| last3 = McKenney \| first3 = JK. \| last4 = Hansel \| first4 = DE. \| last5 = Westfall \| first5 = DE. \| last6 = Parakh \| first6 = R. \| last7 = Mohanty \| first7 = SK. \| last8 = Balzer \| first8 = B. \| last9 = Amin \| first9 = MB. \| title = Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. \| journal = Am J Surg Pathol \| volume = 37 \| issue = 12 \| pages = 1815-23 \| month = Dec \| year = 2013 \| doi = 10.1097/PAS.0000000000000114 \| PMID = 24225842 }}</ref>		*CD44 -ve.<ref name=pmid24225842>{{Cite journal \| last1 = Aron \| first1 = M. \| last2 = Luthringer \| first2 = DJ. \| last3 = McKenney \| first3 = JK. \| last4 = Hansel \| first4 = DE. \| last5 = Westfall \| first5 = DE. \| last6 = Parakh \| first6 = R. \| last7 = Mohanty \| first7 = SK. \| last8 = Balzer \| first8 = B. \| last9 = Amin \| first9 = MB. \| title = Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. \| journal = Am J Surg Pathol \| volume = 37 \| issue = 12 \| pages = 1815-23 \| month = Dec \| year = 2013 \| doi = 10.1097/PAS.0000000000000114 \| PMID = 24225842 }}</ref>
	**Positive in ''indeterminant'' and ''negative''.		**Positive in ''indeterminant'' and ''negative''.

			====Others====
			*AMACR +ve (80% and 50% of untreated and treated CIS respectively<ref name=pmid24225842/>).

	===Images===		===Images===

Michael: /* Gross */

2015-06-17T16:55:40Z

Gross

← Older revision		Revision as of 16:55, 17 June 2015
Line 49:		Line 49:

	==Gross==		==Gross==
	*~~Erythema~~ or edema, may be unremarkable.<ref name=pmid19176205>{{Cite journal \| last1 = Nese \| first1 = N. \| last2 = Gupta \| first2 = R. \| last3 = Bui \| first3 = MH. \| last4 = Amin \| first4 = MB. \| title = Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. \| journal = J Natl Compr Canc Netw \| volume = 7 \| issue = 1 \| pages = 48-57 \| month = Jan \| year = 2009 \| doi = \| PMID = 19176205 }}</ref>		*Flat lesion - erythema or edema, may be unremarkable.<ref name=pmid19176205>{{Cite journal \| last1 = Nese \| first1 = N. \| last2 = Gupta \| first2 = R. \| last3 = Bui \| first3 = MH. \| last4 = Amin \| first4 = MB. \| title = Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. \| journal = J Natl Compr Canc Netw \| volume = 7 \| issue = 1 \| pages = 48-57 \| month = Jan \| year = 2009 \| doi = \| PMID = 19176205 }}</ref>

	==Microscopic==		==Microscopic==

Michael at 16:54, 17 June 2015

2015-06-17T16:54:42Z

← Older revision		Revision as of 16:54, 17 June 2015
Line 27:		Line 27:
	\| Prognosis =		\| Prognosis =
	\| Other =		\| Other =
	\| ClinDDx = invasive (flat) [[urothelial carcinoma]]		\| ClinDDx = invasive (flat) [[urothelial carcinoma]], inflammation (cystitis)
	\| Tx =		\| Tx =
	}}		}}

Michael at 16:53, 17 June 2015

2015-06-17T16:53:52Z

← Older revision		Revision as of 16:53, 17 June 2015
Line 24:		Line 24:
	\| Bloodwork =		\| Bloodwork =
	\| Rads =		\| Rads =
	\| Endoscopy =		\| Endoscopy = erythema or edema, may be unremarkable
	\| Prognosis =		\| Prognosis =
	\| Other =		\| Other =
Line 47:		Line 47:
	*Urothelial carcinoma in situ (high-grade dysplasia).		*Urothelial carcinoma in situ (high-grade dysplasia).
	*Invasive [[urothelial carcinoma]].		*Invasive [[urothelial carcinoma]].

			==Gross==
			*Erythema or edema, may be unremarkable.<ref name=pmid19176205>{{Cite journal \| last1 = Nese \| first1 = N. \| last2 = Gupta \| first2 = R. \| last3 = Bui \| first3 = MH. \| last4 = Amin \| first4 = MB. \| title = Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. \| journal = J Natl Compr Canc Netw \| volume = 7 \| issue = 1 \| pages = 48-57 \| month = Jan \| year = 2009 \| doi = \| PMID = 19176205 }}</ref>

	==Microscopic==		==Microscopic==

Michael: touch

2015-01-12T13:36:48Z

touch

← Older revision		Revision as of 13:36, 12 January 2015
Line 1:		Line 1:
	{{ Infobox diagnosis		{{ Infobox diagnosis
	\| Name = {{PAGENAME}}		\| Name = {{PAGENAME}}
	\| Image = Urothelial carcinoma in situ -- very high mag.jpg		\| Image = Urothelial carcinoma in situ -- very high mag.jpg
	\| Width =		\| Width =
	\| Caption = Urothelial carcinoma in situ. [[H&E stain]].		\| Caption = Urothelial carcinoma in situ. [[H&E stain]].

Michael: /* IHC */

2014-07-24T05:55:13Z

IHC

← Older revision		Revision as of 05:55, 24 July 2014
Line 81:		Line 81:

	==IHC==		==IHC==
	ISUP consensus panel:<ref name=pmid25025364 >{{cite journal \|author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' \|title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference \|journal=Am. J. Surg. Pathol. \|volume=38 \|issue=8 \|pages=1017–22 \|year=2014 \|month=August \|pmid=25025364 \|doi=10.1097/PAS.0000000000000254 \|url=}}</ref>		[[ISUP]] consensus panel:<ref name=pmid25025364 >{{cite journal \|author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' \|title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference \|journal=Am. J. Surg. Pathol. \|volume=38 \|issue=8 \|pages=1017–22 \|year=2014 \|month=August \|pmid=25025364 \|doi=10.1097/PAS.0000000000000254 \|url=}}</ref>
	*CK20 +ve in deep cells.		*CK20 +ve in deep cells.
	**Normal urothelium -- only the umbrella cells.		**Normal urothelium -- only the umbrella cells.

Michael: /* IHC */

2014-07-22T02:27:31Z

IHC

← Older revision		Revision as of 02:27, 22 July 2014
Line 81:		Line 81:

	==IHC==		==IHC==
	~~Recommended by~~ ISUP consensus panel:<ref name=pmid25025364 >{{cite journal \|author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' \|title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference \|journal=Am. J. Surg. Pathol. \|volume=38 \|issue=8 \|pages=1017–22 \|year=2014 \|month=August \|pmid=25025364 \|doi=10.1097/PAS.0000000000000254 \|url=}}</ref>		ISUP consensus panel:<ref name=pmid25025364 >{{cite journal \|author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' \|title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference \|journal=Am. J. Surg. Pathol. \|volume=38 \|issue=8 \|pages=1017–22 \|year=2014 \|month=August \|pmid=25025364 \|doi=10.1097/PAS.0000000000000254 \|url=}}</ref>
	*CK20 +ve in deep cells.		*CK20 +ve in deep cells.
	**Normal urothelium -- only the umbrella cells.		**Normal urothelium -- only the umbrella cells.
	*p53 +ve.		*p53 +ve.
	*CD44 -ve.		*CD44 -ve.
			**Positive in ''indeterminant'' and ''negative''.

	===~~More panels~~===		===Another panel===
	Another panel for benign urothelium versus CIS:<ref name=pmid16932015>{{Cite journal \| last1 = Yin \| first1 = H. \| last2 = He \| first2 = Q. \| last3 = Li \| first3 = T. \| last4 = Leong \| first4 = AS. \| title = Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. \| journal = Appl Immunohistochem Mol Morphol \| volume = 14 \| issue = 3 \| pages = 260-5 \| month = Sep \| year = 2006 \| doi = \| PMID = 16932015 }}</ref>		Another panel for benign urothelium versus CIS:<ref name=pmid16932015>{{Cite journal \| last1 = Yin \| first1 = H. \| last2 = He \| first2 = Q. \| last3 = Li \| first3 = T. \| last4 = Leong \| first4 = AS. \| title = Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. \| journal = Appl Immunohistochem Mol Morphol \| volume = 14 \| issue = 3 \| pages = 260-5 \| month = Sep \| year = 2006 \| doi = \| PMID = 16932015 }}</ref>
	*[[CK20]] +ve in deep cells (23/26 cases).		*[[CK20]] +ve in deep cells (23/26 cases).
Line 94:		Line 95:
	**Normal ~10% of cells, confined to basal aspect.		**Normal ~10% of cells, confined to basal aspect.
	*CD44 -ve.<ref name=pmid24225842>{{Cite journal \| last1 = Aron \| first1 = M. \| last2 = Luthringer \| first2 = DJ. \| last3 = McKenney \| first3 = JK. \| last4 = Hansel \| first4 = DE. \| last5 = Westfall \| first5 = DE. \| last6 = Parakh \| first6 = R. \| last7 = Mohanty \| first7 = SK. \| last8 = Balzer \| first8 = B. \| last9 = Amin \| first9 = MB. \| title = Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. \| journal = Am J Surg Pathol \| volume = 37 \| issue = 12 \| pages = 1815-23 \| month = Dec \| year = 2013 \| doi = 10.1097/PAS.0000000000000114 \| PMID = 24225842 }}</ref>		*CD44 -ve.<ref name=pmid24225842>{{Cite journal \| last1 = Aron \| first1 = M. \| last2 = Luthringer \| first2 = DJ. \| last3 = McKenney \| first3 = JK. \| last4 = Hansel \| first4 = DE. \| last5 = Westfall \| first5 = DE. \| last6 = Parakh \| first6 = R. \| last7 = Mohanty \| first7 = SK. \| last8 = Balzer \| first8 = B. \| last9 = Amin \| first9 = MB. \| title = Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. \| journal = Am J Surg Pathol \| volume = 37 \| issue = 12 \| pages = 1815-23 \| month = Dec \| year = 2013 \| doi = 10.1097/PAS.0000000000000114 \| PMID = 24225842 }}</ref>
	**Positive in ''indeterminant'' and ''negative''.

	IHC without CD44:<ref>{{Cite journal \| last1 = Lopez-Beltran \| first1 = A. \| last2 = Jimenez \| first2 = RE. \| last3 = Montironi \| first3 = R. \| last4 = Patriarca \| first4 = C. \| last5 = Blanca \| first5 = A. \| last6 = Menendez \| first6 = CL. \| last7 = Algaba \| first7 = F. \| last8 = Cheng \| first8 = L. \| title = Flat urothelial carcinoma in situ of the bladder with glandular differentiation. \| journal = Hum Pathol \| volume = 42 \| issue = 11 \| pages = 1653-9 \| month = Nov \| year = 2011 \| doi = 10.1016/j.humpath.2010.12.024 \| PMID = 21531007 }}</ref>
	*p53 +ve.
	*Ki-67 high.
	**Positive in ''indeterminant'' and ''negative''.		**Positive in ''indeterminant'' and ''negative''.

Michael: /* IHC */

2014-07-22T02:24:29Z

IHC

← Older revision		Revision as of 02:24, 22 July 2014
Line 82:		Line 82:
	==IHC==		==IHC==
	Recommended by ISUP consensus panel:<ref name=pmid25025364 >{{cite journal \|author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' \|title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference \|journal=Am. J. Surg. Pathol. \|volume=38 \|issue=8 \|pages=1017–22 \|year=2014 \|month=August \|pmid=25025364 \|doi=10.1097/PAS.0000000000000254 \|url=}}</ref>		Recommended by ISUP consensus panel:<ref name=pmid25025364 >{{cite journal \|author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' \|title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference \|journal=Am. J. Surg. Pathol. \|volume=38 \|issue=8 \|pages=1017–22 \|year=2014 \|month=August \|pmid=25025364 \|doi=10.1097/PAS.0000000000000254 \|url=}}</ref>
	*CK20 +ve in deep cells ~~(23/26 cases)~~.		*CK20 +ve in deep cells.
	**Normal urothelium -- only the umbrella cells.		**Normal urothelium -- only the umbrella cells.
	*p53		*p53 +ve.
	*CD44 -ve.		*CD44 -ve.

			===More panels===
	Another panel for benign urothelium versus CIS:<ref name=pmid16932015>{{Cite journal \| last1 = Yin \| first1 = H. \| last2 = He \| first2 = Q. \| last3 = Li \| first3 = T. \| last4 = Leong \| first4 = AS. \| title = Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. \| journal = Appl Immunohistochem Mol Morphol \| volume = 14 \| issue = 3 \| pages = 260-5 \| month = Sep \| year = 2006 \| doi = \| PMID = 16932015 }}</ref>		Another panel for benign urothelium versus CIS:<ref name=pmid16932015>{{Cite journal \| last1 = Yin \| first1 = H. \| last2 = He \| first2 = Q. \| last3 = Li \| first3 = T. \| last4 = Leong \| first4 = AS. \| title = Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. \| journal = Appl Immunohistochem Mol Morphol \| volume = 14 \| issue = 3 \| pages = 260-5 \| month = Sep \| year = 2006 \| doi = \| PMID = 16932015 }}</ref>
	*[[CK20]] +ve in deep cells (23/26 cases).		*[[CK20]] +ve in deep cells (23/26 cases).

Michael: /* IHC */

2014-07-22T02:23:33Z

IHC

← Older revision		Revision as of 02:23, 22 July 2014
Line 81:		Line 81:

	==IHC==		==IHC==
	~~Features~~:<ref>{{~~Cite~~ journal \| last1 = Lopez-Beltran \| first1 = A. \| last2 = Jimenez \| first2 = RE. \| last3 = Montironi \| first3 = R. \| last4 = Patriarca \| first4 = C. \| last5 = Blanca \| first5 = A. \| last6 = Menendez \| first6 = CL. \| last7 = Algaba \| first7 = F. \| ~~last8~~ = ~~Cheng \| first8 = L~~. \| title = ~~Flat urothelial carcinoma~~ in ~~situ~~ of the ~~bladder with glandular differentiation.~~ \| journal = ~~Hum~~ Pathol \| volume = 42 \| issue = 11 \| pages = ~~1653-9~~ \| month = ~~Nov~~ \| ~~year~~ = ~~2011~~ \| doi = 10.~~1016~~/j.~~humpath.2010.12.024~~ \| ~~PMID~~ = ~~21531007~~ }}</ref>		Recommended by ISUP consensus panel:<ref name=pmid25025364 >{{cite journal \|author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' \|title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference \|journal=Am. J. Surg. Pathol. \|volume=38 \|issue=8 \|pages=1017–22 \|year=2014 \|month=August \|pmid=25025364 \|doi=10.1097/PAS.0000000000000254 \|url=}}</ref>
	*~~p53~~ +ve.		*CK20 +ve in deep cells (23/26 cases).
	*Ki-~~67 high~~.		**Normal urothelium -- only the umbrella cells.
			*p53
			*CD44 -ve.

	~~Benign~~ urothelium versus CIS:<ref name=pmid16932015>{{Cite journal \| last1 = Yin \| first1 = H. \| last2 = He \| first2 = Q. \| last3 = Li \| first3 = T. \| last4 = Leong \| first4 = AS. \| title = Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. \| journal = Appl Immunohistochem Mol Morphol \| volume = 14 \| issue = 3 \| pages = 260-5 \| month = Sep \| year = 2006 \| doi = \| PMID = 16932015 }}</ref>		Another panel for benign urothelium versus CIS:<ref name=pmid16932015>{{Cite journal \| last1 = Yin \| first1 = H. \| last2 = He \| first2 = Q. \| last3 = Li \| first3 = T. \| last4 = Leong \| first4 = AS. \| title = Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. \| journal = Appl Immunohistochem Mol Morphol \| volume = 14 \| issue = 3 \| pages = 260-5 \| month = Sep \| year = 2006 \| doi = \| PMID = 16932015 }}</ref>
	*[[CK20]] +ve in deep cells (23/26 cases).		*[[CK20]] +ve in deep cells (23/26 cases).
	**Normal urothelium -- only the umbrella cells.		**Normal urothelium -- only the umbrella cells.
Line 91:		Line 93:
	**Normal ~10% of cells, confined to basal aspect.		**Normal ~10% of cells, confined to basal aspect.
	*CD44 -ve.<ref name=pmid24225842>{{Cite journal \| last1 = Aron \| first1 = M. \| last2 = Luthringer \| first2 = DJ. \| last3 = McKenney \| first3 = JK. \| last4 = Hansel \| first4 = DE. \| last5 = Westfall \| first5 = DE. \| last6 = Parakh \| first6 = R. \| last7 = Mohanty \| first7 = SK. \| last8 = Balzer \| first8 = B. \| last9 = Amin \| first9 = MB. \| title = Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. \| journal = Am J Surg Pathol \| volume = 37 \| issue = 12 \| pages = 1815-23 \| month = Dec \| year = 2013 \| doi = 10.1097/PAS.0000000000000114 \| PMID = 24225842 }}</ref>		*CD44 -ve.<ref name=pmid24225842>{{Cite journal \| last1 = Aron \| first1 = M. \| last2 = Luthringer \| first2 = DJ. \| last3 = McKenney \| first3 = JK. \| last4 = Hansel \| first4 = DE. \| last5 = Westfall \| first5 = DE. \| last6 = Parakh \| first6 = R. \| last7 = Mohanty \| first7 = SK. \| last8 = Balzer \| first8 = B. \| last9 = Amin \| first9 = MB. \| title = Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. \| journal = Am J Surg Pathol \| volume = 37 \| issue = 12 \| pages = 1815-23 \| month = Dec \| year = 2013 \| doi = 10.1097/PAS.0000000000000114 \| PMID = 24225842 }}</ref>
			**Positive in ''indeterminant'' and ''negative''.

			IHC without CD44:<ref>{{Cite journal \| last1 = Lopez-Beltran \| first1 = A. \| last2 = Jimenez \| first2 = RE. \| last3 = Montironi \| first3 = R. \| last4 = Patriarca \| first4 = C. \| last5 = Blanca \| first5 = A. \| last6 = Menendez \| first6 = CL. \| last7 = Algaba \| first7 = F. \| last8 = Cheng \| first8 = L. \| title = Flat urothelial carcinoma in situ of the bladder with glandular differentiation. \| journal = Hum Pathol \| volume = 42 \| issue = 11 \| pages = 1653-9 \| month = Nov \| year = 2011 \| doi = 10.1016/j.humpath.2010.12.024 \| PMID = 21531007 }}</ref>
			*p53 +ve.
			*Ki-67 high.
	**Positive in ''indeterminant'' and ''negative''.		**Positive in ''indeterminant'' and ''negative''.